Cyclophosphamide is an antineoplastic alkylating agent, used in the treatment of many cancers.

**INN**
Cyclophosphamide

**ATC codes**
L01AA01

**Medicine type**
Chemical agent

**EML status history**
- First added in 1977 (TRS 615) for Diffuse large B-cell lymphomas
- Added in 1977 (TRS 615) for Chronic lymphocytic leukaemia or small lymphocytic lymphoma
- Added in 1977 (TRS 615) for Malignant neoplasms of breast
- Added in 1977 (TRS 615) for Malignant trophoblastic neoplasms of placenta
- Added in 1977 (TRS 615) for Follicular lymphoma
- Added in 1977 (TRS 615) for Other specified malignant neoplasms of breast
- Added in 1977 (TRS 615) for Hodgkin lymphoma
- Added in 1977 (TRS 615) for Rhabdomyosarcoma primary site
- Added in 1977 (TRS 615) for Burkitt lymphoma including Burkitt leukaemia
- Added in 1977 (TRS 615) for Lymphoid leukaemia, not elsewhere classified
- Added in 1977 (TRS 615) for Ewing sarcoma of bone and articular cartilage of unspecified sites
- Added in 1977 (TRS 615) for Unspecified malignant neoplasms of ill-defined or unspecified sites
- Removed in 2015 (TRS 994) for Unspecified malignant neoplasms of ill-defined or unspecified sites
- Added in 2019 (TRS 1021) for Plasma cell myeloma
- Added in 2021 (TRS 1035) for Other specified gliomas of brain
- Added in 2021 (TRS 1035) for Malignant neoplasms of kidney, except renal pelvis
- Added in 2023 (TRS 1049) for Anaplastic large cell lymphoma, ALK-positive
- Added in 2023 (TRS 1049) for Anaplastic large cell lymphoma, ALK-negative

**Wikipedia**
Cyclophosphamide

**DrugBank**
Cyclophosphamide

**Recommendations**
Cytotoxic medicines

Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Oral > Solid > dosage form: 25 mg; 50 mg
Oral > Solid: 25 mg tablet
Parenteral > General injections > unspecified: 500 mg in vial powder for injection

Indications

- Diffuse large B-cell lymphomas
- Chronic lymphocytic leukaemia or small lymphocytic lymphoma
- Malignant neoplasms of breast
- Malignant trophoblastic neoplasms of placenta
- Follicular lymphoma
- Other specified malignant neoplasms of breast
- Hodgkin lymphoma
- Rhabdomyosarcoma primary site
- Ewing sarcoma of bone and articular cartilage of unspecified sites
- Lymphoid leukaemia, not elsewhere classified
- Burkitt lymphoma including Burkitt leukaemia
- Unspecified malignant neoplasms of ill-defined or unspecified sites
- Plasma cell myeloma
- Other specified gliomas of brain
- Malignant neoplasms of kidney, except renal pelvis
- Anaplastic large cell lymphoma, ALK-positive
- Anaplastic large cell lymphoma, ALK-negative